Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates
August 04, 2021 17:30 ET
|
Tarsus Pharmaceuticals, Inc
Announced positive results of the Saturn-1 pivotal trial evaluating TP-03 for the treatment of Demodex blepharitis; results presented at the 2021 American Society of Cataract and Refractive Surgery...
Clearside Biomedical to Participate in Two Upcoming Investor Conferences in August 2021
August 04, 2021 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
Global Corneal Implants Market (2021 to 2026) - Growth, Trends, COVID-19 Impact and Forecasts
August 04, 2021 04:53 ET
|
Research and Markets
Dublin, Aug. 04, 2021 (GLOBE NEWSWIRE) -- The "Corneal Implants Market- Growth, Trends, COVID-19 Impact and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering. The...
Eyenuk AI Technology Selected for Diabetic Eye Testing in Vietnam Supported by The Fred Hollows Foundation
July 26, 2021 09:00 ET
|
Eyenuk, Inc.
LOS ANGELES, July 26, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021
July 24, 2021 18:00 ET
|
Tarsus Pharmaceuticals, Inc
New Saturn-1 data demonstrated a strong patient responder rate with 95% of Demodex blepharitis patients treated with TP-03 achieving ≤0.5 mites per lash and 93% improving by at least one collarette...
Eyenuk Announces $6.2 Million Financing to Accelerate Adoption of FDA-cleared AI Technology for Detection of Diabetic Retinopathy
July 20, 2021 08:00 ET
|
Eyenuk, Inc.
LOS ANGELES, July 20, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...
Dry Eye Disease Clinical Landscape Report 2021: Novartis Leads Industry Sponsors with the Highest Overall Number of Clinical Trials, Followed by AbbVie
July 08, 2021 07:08 ET
|
Research and Markets
Dublin, July 08, 2021 (GLOBE NEWSWIRE) -- The "Market Spotlight: Dry Eye Disease" report has been added to ResearchAndMarkets.com's offering. This Market Spotlight report covers the Systemic Lupus...
Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
July 07, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...
Midwest Vision Partners Selects Nextech’s IntelleChartPRO
July 06, 2021 13:30 ET
|
Nextech Systems, Inc.
TAMPA, Fla., July 06, 2021 (GLOBE NEWSWIRE) -- Nextech Systems, a leading provider of healthcare technology solutions for specialty providers, today announced a new partnership with Midwest Vision...
Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis
June 18, 2021 16:05 ET
|
Tarsus Pharmaceuticals, Inc
IRVINE, Calif., June 18, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to focus on unmet needs and apply...